Inactive Instrument

All News Ampliphi Biosciences Corp Nyse

Equities

APHB

US03211P2020

All News

Unlock all the news: Be the first to know and act before the market!

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection	07-12	AQ
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024	07-11	AQ
Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection	07-11	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000	05-07	MT
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K	03-22	PU
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M	03-21	MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-21	CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	03-04	MT
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update	11-15	AQ
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference	30/10/23	CI
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus	27/09/23	AQ
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus	26/09/23	CI
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference	22/09/23	AQ
Armata Pharmaceuticals, Inc. Announces CFO Changes	20/09/23	CI
Armata Pharmaceuticals, Inc. Announces Executive Changes	20/09/23	CI
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update	15/08/23	AQ
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Ampliphi Biosciences Corp Nyse

Equities

APHB

US03211P2020

All News

Filters